Corteva Inc. Common Stock vs Danaher Corporation — how do they compare? Corteva Inc. Common Stock trades at $13.36 (market cap $9.17B), while Danaher Corporation trades at $219.26 (market cap $152.87B). The key difference: Danaher Corporation is far larger — about 16.7× Corteva Inc. Common Stock's market cap, and Corteva Inc. Common Stock pays the higher dividend (5.24%). Which is the better fit depends on your goals — on Pluang, investors hold Corteva Inc. Common Stock for 0 Days and Danaher Corporation for 69 Days on average.
| CTVA | DHR | |
|---|---|---|
Market Cap | $9.17B | $152.87B |
Volume | 35,183,471 | 5,228,698 |
Sector | Basic Materials | Health |
52-Week High | $90.51 | $242.05 |
52-Week Low | $11.92 | $161.91 |
Typical Hold Time | 0 Days | 69 Days |
Enterprise Value | $11.68B | $175.08B |
Dividend Yield | 5.24% | 0.74% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Corteva provides seeds, crop protection products, and digital tools for agriculture. Its products are used by farmers to manage crop production and protect yields.
Read more on CTVA →In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →